Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E ...

In patients with chronic spontaneous urticaria, biomarkers such as a positive chronic urticaria index and low blood histamine ...

Dupilumab enhances quality of life in chronic urticaria patients unresponsive to antihistamines. Find out how treatment can ...

CHEST guidelines on biologic management in severe adult asthma offers recommendations on choosing and switching among biologic therapies.

The FDA's approval of the new dosing option for Omlyclo addresses the diverse needs of patients with allergic and ...

Celltrion receives US FDA approval of 300mg strength of Omlyclo, the first and only interchangeable biosimilar to Xolair: Incheon, South Korea Thursday, December 4, 2025, 11:00 Hr ...

The addition of a new 300mg presentation allows for greater dosing flexibility to ease overall treatment burden and discomfort. The interchangeable biosimilar was originally approved in March 2025 in ...

By blocking a molecule that pushes the immune system into overdrive, a vaccine protects mice from life-threatening ...

Researchers have engineered an experimental vaccine that can provide year-long protection against anaphylaxis in mice. This ...

Celltrion secures US approval for 300mg OMLYCLO syringe, completes full PFS lineup Celltrion completes omalizumab prefilled ...

Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable ...

Celltrion said on the 25th that Omlyclo (OMLYCLO), a treatment for chronic spontaneous urticaria launched in Europe in Sep., has been released in major countries, including Germany, Spain, the United ...